Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Detalles Bibliográficos
Autores principales: Ludwig, H, Weisel, K, Petrucci, M T, Leleu, X, Cafro, A M, Garderet, L, Leitgeb, C, Foa, R, Greil, R, Yakoub-Agha, I, Zboralski, D, Vauléon, S, Dümmler, T, Beyer, D, Kruschinski, A, Riecke, K, Baumann, M, Engelhardt, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383929/
https://www.ncbi.nlm.nih.gov/pubmed/28074071
http://dx.doi.org/10.1038/leu.2017.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383929/
https://www.ncbi.nlm.nih.gov/pubmed/28074071
http://dx.doi.org/10.1038/leu.2017.5

Ejemplares similares